Recent Updates
Recently added Catalysts
ICLR Negative Sentiment

ICON plc Provides Update on Vaccine Study On

Key Takeaway: ICON plc announced a delay in their large-scale next generation COVID vaccine study by 90 days, which will impact their revenue for the first half of 2025. Despite this setback, the company maintains its financial guidance for the full year of 2025. The delay was highlighted during an earnings call, indicating ongoing challenges with the study's timeline. The situation emphasizes the uncertainties surrounding clinical studies and their implications on financial performance.
Price reaction · baseline $190.02 (2025-02-28 close) · clean, no other ICLR news in the window
day 0 close
-2.7%
day 1
-3.4%
day 3
-2.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • The vaccine study has been delayed by 90 days, impacting revenue.
  • The delay suggests potential challenges in meeting financial expectations.

Full Press Release Details

ICON plc Provides Update on Vaccine Study
On March 3, 2025, ICON plc, announced that the large-scale next generation COVID vaccine study that was highlighted on our earnings call on February 20, 2025 as actively screening and moving forward as planned, has now also been delayed by the sponsor. Current information indicates a delay of 90 days, suggesting that the study will re-commence late in Q2 2025. While the delay will impact our revenue for the first half of 2025, at this time there is no change to our financial guidance for the full year 2025.
This statement contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this statement. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word expected and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http www.sec.gov.

Frequently Asked Questions

What is the current status of the COVID vaccine study?

The COVID vaccine study has been delayed by 90 days and will restart late in Q2 2025.

How will the delay affect ICON's revenue?

The delay will impact ICON's revenue for the first half of 2025.

Is there a change in ICON's financial guidance for 2025?

No, there is no change to ICON's financial guidance for the full year 2025.

Are the forward-looking statements in the announcement guaranteed?

No, forward-looking statements are not guarantees and actual results may vary.

Where can I find more information on risks and uncertainties?

More information is available in ICON's SEC reports, accessible at www.sec.gov.

Last updated: Mar 3, 2025